WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.238.250.73'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

MYCO – Shroom Investor 🍄

MYCO

Mydecine Innovations Group Inc.

Financials1282 views16 min read

Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

Mydecine Innovations Group

DENVER, Nov. 14, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial results for the nine months ended September 30, 2022. Company Highlights In 2022, Mydecin... Read More...

Capital Raise1384 views5 min read

Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors

Mydecine Innovations Group

DENVER, Aug. 19, 2022 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that it has... Read More...

Financials49 views50 min read

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022

Mydecine Innovations Group

DENVER, Aug. 15, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results for the six months ended June 30, 2022. Financial Results for the Six Months Ended June 30, 2022 Net Los... Read More...

Financials1059 views5 min read

Mydecine Announces First Quarter 2022 Financial Results and Highlights

Mydecine Innovations Group

DENVER, May 16, 2022 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a business update for the first quarter of 2022. “Our team had an ext... Read More...

133 views4 min read

Mydecine To Attend March Investor Conferences

Mydecine Innovations Group

DENVER, March 03, 2022 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the company will be attending three conferences for investors in March – the 34th Annual Roth Conf... Read More...

425 views4 min read

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Mydecine Innovations Group

VANCOUVER, British Columbia, Feb. 03, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s Board of Directors. Dr. Hale ... Read More...

875 views4 min read

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Mydecine Innovations Group

VANCOUVER, British Columbia, Jan. 07, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that the company has engaged JBN Partners, LLC (“JBN”) to in... Read More...

1066 views8 min read

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Mydecine Innovations Group

DENVER, Dec. 09, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has entered into an agreement with an investor to complete a non-brokered priv... Read More...

Financials138 views46 min read

Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update

Mydecine Innovations Group

--To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple Molecules for a Variety of Indications -- DENVER, Nov. 16, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a ... Read More...

1421 views5 min read

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients

Mydecine Innovations Group

DENVER, Nov. 03, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced the filing of a technology patent that allows for the creation of formulations th... Read More...

133 views4 min read

Mydecine to Participate in Wonderland: Miami on November 8-9, 2021

Mydecine Innovations Group

DENVER, Oct. 29, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company focused on the treatment of mental health disorders and addiction, today announced that it will participate in Microdose’s Wonderland: Miami to be held at the Adrienne Arsht... Read More...

1164 views5 min read

Mydecine to Participate in Upcoming Conferences in September 2021

Mydecine Innovations Group

DENVER, Sept. 02, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and addiction, today announced that Josh Bartch, CEO of Mydecine, will participate in three upcoming conferences: H... Read More...

Calendar1183 views5 min read

Mydecine Innovations Group Announces Mailing of Management Information Circular and Provides Update on Spin-Out of U.S. Cannabis Assets

Mydecine Innovations Group

DENVER, Aug. 24, 2021 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), is pleased to announce that it has filed and mailed its management information circular (the “Information Circular”) and related meeting and proxy materials for the annual general and special meeting of the shareholders of the ... Read More...

1447 views4 min read

Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine

Mydecine Innovations Group

DENVER, Aug. 18, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announces it has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, with research to be led by Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University, Dr. Matthew W. Johnson, Ph. D. The Johns Hopkins... Read More...

187 views4 min read

Mydecine to Participate in Upcoming Investor Events in August 2021

Mydecine Innovations Group

DENVER, July 28, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that Josh Bartch, CEO of Mydecine, will pa... Read More...

1256 views5 min read

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

Mydecine Innovations Group

DENVER, July 21, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that the Company has filed a new patent fo... Read More...

22 views6 min read

Mydecine Innovations Group Announces Launch of Mindleap Version 2.0

Mydecine Innovations Group

The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics DENVER, July 13, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and ac... Read More...

472 views7 min read

Mydecine Innovations Group Upsizes Previously Announced Bought Deal

Mydecine Innovations Group

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/DENVER, Jan. 14, 2021 - Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natu... Read More...

458 views6 min read

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Mydecine Innovations Group

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/DENVER, Jan. 14, 2021 - Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natu... Read More...

1209 views4 min read

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

Mydecine Innovations Group

DENVER, Jan. 05, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled... Read More...

153 views6 min read

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group

Leading FDA consultancy firm to advise on drug development and clinical trial pipelineDENVER, Dec. 15, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic m... Read More...

796 views5 min read

Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

Mydecine Innovations Group

Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybinDENVER, Dec. 08, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company com... Read More...

Financials1095 views2 min read

Mydecine Innovations Group to Restate Financial Statements

Mydecine Innovations Group

VANCOUVER, British Columbia, Nov. 24, 2020 -- Mydecine Innovations Group Inc. (the “Company”) (CSE:MYCO | OTC:MYCOF) announces that its previously issued financial statements for the fiscal year ended December 31, 2019, and the three- and six-month periods ended March 31, 2020 and June 30, 2020, any corresponding management’s discussion a... Read More...

478 views4 min read

Mydecine Innovations Group Retains KCSA Strategic Communications

Mydecine Innovations Group

KCSA to provide Public Relations and Social Media CounselNEW YORK, Nov. 6, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced th... Read More...

1 views7 min read

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

Mydecine Innovations Group

VANCOUVER, British Columbia, Oct. 19, 2020 -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the ... Read More...

380 views4 min read

Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin

Mydecine Innovations Group

VANCOUVER, British Columbia, Oct. 07, 2020 -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of mat... Read More...

1 views8 min read

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today

Mydecine Innovations Group

Picture 1Figure 1Figure 1DENVER, Sept. 30, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today:... Read More...

1105 views11 min read

Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration

Mydecine Innovations Group

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/42c4893d-6232-4d13-9d58-b3098cc222bbDENVER, Sept. 24, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that its subsidiary Mindleap Health’s (“Mindleap” ) telehealth platform wil... Read More...

1369 views4 min read

Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets

Mydecine Innovations Group

DENVER, Sept. 15, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine"), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value.Topics that the special committee will discuss include, but limited to, a potential spin out of certain company ... Read More...

Calendar478 views4 min read

Mydecine Innovations Group Would Like to Give Thanks to its Shareholders for Extending the Lockup on the Five Cent Placement for Another 120 Days

Mydecine Innovations Group

DENVER, Sept. 03, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine", “MIG”) is pleased to announce that its shareholders have agreed to extend lock-up restrictions in respect to 35,737,460 shares of the Company that were due to be released on September 6, 2020, for an additional 120 days.Under the ter... Read More...

941 views16 min read

Mydecine Innovations Group Provides Inaugural Corporate Update in the Expanding Psychedelic Medicines Sector

Mydecine Innovations Group

DENVER, Aug. 12, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" “MIG”), is pleased to provide a corporate update regarding recent advancements and achievements that continues to add shareholder value and position Mydecine as a genuine leader in the ever-expanding fungi and psychedelic sectors. Throug... Read More...

852 views4 min read

Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

Mydecine Innovations Group

VANCOUVER, British Columbia, June 23, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine") is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.The new members of the science team will provide scientific expertise and corporate strategy support as Mydeci... Read More...

M & A903 views5 min read

Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth Platform

Mydecine Innovations Group

VANCOUVER, British Columbia , June 17, 2020 -- Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (MYCO.CN) (OTCMKTS:MYCOF) (FSE: 0NF) ("Mydecine") is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. ("Mindleap") for the acquisition of a 100% interest in MindLeap's Digital... Read More...

938 views7 min read

Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation

Mydecine Innovations Group

VANCOUVER, British Columbia , June 12, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (NLBIF) (0NF.F) ("Mydecine"), is pleased to announce the establishment of a research division agreement with Applied Pharmaceutical Innovation ("API"), a translational commercial drug development institute hosted in the University of Alberta's Faculty... Read More...

Make smarter investment strategies
with in-depth news reports

Join our subscribers!